Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sanofi ( (SNY) ) has provided an update.
In July 2025, Sanofi announced that its SAR446597 therapy received fast track designation from the US FDA for treating geographic atrophy due to age-related macular degeneration, highlighting its potential to address unmet medical needs in retinal diseases. Additionally, Sanofi revealed plans to acquire Vicebio, aiming to expand its respiratory vaccines pipeline, which could enhance its market position and offer new growth opportunities.
The most recent analyst rating on (SNY) stock is a Hold with a $67.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
Spark’s Take on SNY Stock
According to Spark, TipRanks’ AI Analyst, SNY is a Neutral.
Sanofi’s overall stock score reflects strong financial performance and positive earnings call highlights, including robust sales growth and strategic initiatives. However, technical analysis indicates bearish momentum, and cash flow weaknesses along with market uncertainties slightly temper the outlook.
To see Spark’s full report on SNY stock, click here.
More about Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving lives by inventing medicines and vaccines that treat and protect millions globally. The company focuses on addressing serious neuroinflammatory and neurodegenerative diseases, with a strong emphasis on ophthalmology and immune system conditions.
Average Trading Volume: 2,232,619
Technical Sentiment Signal: Hold
Current Market Cap: $118.5B
For an in-depth examination of SNY stock, go to TipRanks’ Overview page.